Here are 1-2 brief analogies for CG Oncology:

• Like Gilead Sciences for bladder cancer: CG Oncology aims to revolutionize bladder cancer treatment with a novel, bladder-sparing drug, much like Gilead Sciences transformed the landscape for Hepatitis C patients with their groundbreaking therapies.
• Like a specialized Vertex Pharmaceuticals for bladder cancer: The company focuses on developing a new backbone therapy for high-risk bladder cancer patients who currently have limited options beyond bladder removal, similar to how Vertex specializes in transformative treatments for cystic fibrosis.

• Cretostimogene (Monotherapy for BCG-unresponsive NMIBC): A late-stage clinical therapeutic being developed as a potential bladder-sparing treatment for high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients who are unresponsive to BCG therapy.
• Cretostimogene in combination with Pembrolizumab (for BCG-unresponsive NMIBC): An investigational therapeutic being evaluated in clinical trials for high-risk NMIBC patients unresponsive to BCG therapy, administered alongside the FDA-approved drug pembrolizumab.
• Cretostimogene (for Intermediate-Risk NMIBC): A clinical-stage therapeutic being assessed for its safety and efficacy as an adjuvant therapy in intermediate-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) patients following transurethral resection of the bladder tumor (TURBT).

CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene, for bladder cancer. As described in the provided background, the company is currently conducting clinical trials (Phase 3 and Phase 2) and has not yet received regulatory approval (e.g., FDA Biologics License Application) to commercialize its therapeutic.

Therefore, CG Oncology does not currently have any major customers for product sales. Its operations are focused on research, development, and securing regulatory approval for cretostimogene.

Merck & Co., Inc. (MRK)

Arthur Kuan, Chairman & Chief Executive Officer

Arthur Kuan was appointed CEO in January 2017. His personal connection to CG Oncology's mission stems from having lost his father to cancer. Kuan was a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform. He also held roles at Themes Investment Partners, a private equity fund, and Dinova Capital, a MedTech incubator fund. Kuan was an early investor in CG Oncology (then Cold Genesys) and joined full-time in 2014 as Vice President of research and clinical project management, becoming CEO in 2016. He holds an M.S. in Biotechnology from Johns Hopkins University and a B.A. in Biology from the University of Pennsylvania. In 2024, Kuan was recognized by EY as an Entrepreneur Of The Year Pacific Southwest Award winner and was previously named a Forbes 30 Under 30 honoree. [cite: 5, 6, 10, 11, 13 of previous thoughts]

Jim DeTore, Interim Principal Financial and Accounting Officer

Jim DeTore was appointed interim principal financial and accounting officer of CG Oncology effective November 17, 2025, through a consulting engagement with Monomoy Advisors, LLC. He has served as Chief Financial Officer at Neurogastrx, Inc. (June 2021 – June 2025), Proteostasis Therapeutics (August 2016 – February 2017), and bluebird bio, Inc. (November 2014 – February 2016). He also provided independent CFO consulting services to various biotechnology and pharmaceutical companies from March 2017 to May 2021. Earlier in his career, he was Vice President of Corporate Finance at Ironwood Pharmaceuticals, where he worked on debt and equity transactions, including the company's IPO. He holds a Bachelor of Science and an MBA from Northeastern University.

Ambaw Bellete, President & Chief Operating Officer

Ambaw Bellete was appointed President and Chief Operating Officer in September 2023. [cite: 17 of previous thoughts] He has over 30 years of experience in the biotech industry, with a strong track record of success in building and managing multidisciplinary teams from pre-launch to commercialization. [cite: 17 of previous thoughts]

Vijay Kasturi, Chief Medical Officer

Vijay Kasturi, M.D., was appointed Chief Medical Officer in September 2023. [cite: 17 of previous thoughts] He brings over 25 years of experience in establishing and executing global and regional strategies that have led to innovative treatment options for patients in hematology, oncology, and urology. [cite: 17 of previous thoughts] Previously, he was Vice President, Clinical Development and Medical Affairs, and a member of the executive leadership team at AVEO. [cite: 17 of previous thoughts] He also served as SVP of Scientific Affairs at FerGene. [cite: 17 of previous thoughts] He is a GU medical oncologist. [cite: 17 of previous thoughts]

Swapnil Bhargava, Chief Technical Officer

Swapnil Bhargava, Ph.D., was appointed Chief Technical Officer in September 2023. [cite: 4, 17 of previous thoughts] He has supported multiple INDs (Investigational New Drug applications) and BLAs (Biologics License Applications) and contributed to bringing various modalities to the clinic and market. [cite: 17 of previous thoughts] Prior to CG Oncology, he was Senior Vice President of CMC Development and GMP Manufacturing at AbCellera, leading Tech Ops, and before that, Vice President for drug substance process development at Seagen. [cite: 17 of previous thoughts] He also worked at Amgen, leading process development efforts. [cite: 17 of previous thoughts] He holds a doctorate in Chemical Engineering from the University of Maryland and a B.S./M.S. from the Indian Institute of Technology (IIT) Delhi. [cite: 17 of previous thoughts]

The key risks to CG Oncology's business are:

1. Failure of Cretostimogene Clinical Trials: The success of CG Oncology's business is highly dependent on the successful completion and positive outcomes of its ongoing clinical trials for cretostimogene, particularly the pivotal Phase 3 BOND-003 trial. The company has reported positive interim data, but explicitly states that "Interim results from these trials may differ from future results of the trials as more patient data become available." A failure to achieve the desired efficacy or safety endpoints in these trials, or a significant deviation from interim results, would severely impact the potential for regulatory approval and commercialization of their primary product candidate.

2. Inability to Obtain Regulatory Approval: Even if clinical trials for cretostimogene are successful, there is no guarantee that CG Oncology will obtain the necessary regulatory approvals from bodies like the U.S. Food and Drug Administration (FDA) for marketing. The company has received fast track designation, but clarifies that "Fast track designation may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that cretostimogene will receive marketing approval." A failure to secure regulatory approval would prevent the company from commercializing cretostimogene, rendering their development efforts and investments largely unproductive.

Expected Drivers of Future Revenue Growth for CG Oncology (CGON) Over the Next 2-3 Years

CG Oncology's future revenue growth is anticipated to be driven by several key factors related to the development and commercialization of its lead product candidate, cretostimogene, for bladder cancer:

1. Successful Commercial Launch of Cretostimogene for High-Risk BCG-Unresponsive NMIBC: A primary driver will be the potential regulatory approval and subsequent commercial launch of cretostimogene as a monotherapy for patients with high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. The company expects to report topline data from its pivotal Phase 3 BOND-003 clinical trial by the end of 2024, which, if successful, could form the basis for a Biologics License Application (BLA) submission to the FDA. The introduction of cretostimogene into this market with significant unmet need would directly contribute to revenue generation.
2. Expansion into New Bladder Cancer Indications and First-Line Therapy: CG Oncology intends to evaluate cretostimogene in treating a range of other bladder cancer indications, including its second Phase 3 clinical trial, PIVOT-006, evaluating adjuvant cretostimogene in intermediate-risk NMIBC patients. The company also believes cretostimogene, if approved, has the potential to serve as first-line therapy. Expanding the addressable patient population beyond BCG-unresponsive NMIBC to include intermediate-risk patients and potentially first-line treatment will significantly broaden the market opportunity and drive revenue growth.
3. Development and Potential Approval of Combination Therapies: The ongoing Phase 2 CORE-001 clinical trial, evaluating cretostimogene in combination with FDA-approved pembrolizumab for high-risk BCG-unresponsive NMIBC, presents another avenue for revenue growth. Positive results and subsequent regulatory approval for combination therapy would expand the utility and market share of cretostimogene, offering a broader range of treatment options and increasing patient access.
4. Addressing the Bacillus Calmette Guerin (BCG) Shortage: Cretostimogene has the potential to alleviate the current market shortage of BCG therapy, which is the standard-of-care for high-risk NMIBC. By offering a viable and effective alternative, particularly one that could potentially serve as first-line therapy, CG Oncology can capture market share from existing treatment gaps and fulfill an urgent clinical need, thereby driving adoption and revenue.

Share Issuance

• CG Oncology completed an initial public offering (IPO) in January 2024, raising approximately $380 million in gross proceeds from selling 20 million shares at $19 per share. The net proceeds from this offering were $399.6 million.
• In December 2024, the company completed a public offering of 8.5 million common stock shares at $28.00 per share, which generated expected gross proceeds of $204.4 million for CG Oncology.
• In January 2026, CG Oncology increased its at-the-market (ATM) common stock program to a maximum aggregate offering price of $550 million. The company had previously sold shares for gross proceeds of $250 million under this program.

Inbound Investments

• CG Oncology closed an oversubscribed $120 million Series E financing round in November 2022, co-led by ORI Capital, Longitude Capital, and Decheng Capital, with additional participation from other investors.
• The company raised $105 million in new funding in March 2025 to accelerate the development and commercialization of its oncolytic immunotherapy.
• As of March 2026, CG Oncology has raised a total of $318 million in funding over six rounds, with its latest funding round being a Series E in August 2023.

Capital Expenditures

• For the last 12 months, CG Oncology's capital expenditures were -$336K.
• Research and development (R&D) expenses, which constitute a primary focus of the company's investment, were $116.6 million for the full year 2025, an increase from $82.1 million in 2024.
• The increased R&D and general & administrative expenses in 2025 reflect expanded clinical trials, manufacturing, and corporate infrastructure, supporting the development of cretostimogene.